Additionally, treatment of the HCC cells with BEZ235-alone or combined with regorafenib significantly reduced the levels of p-mTOR (Ser2448), p-p70S6K (Thr389), p-4EBP1 (Thr37/46) and p-4EBP1 (Thr70), in contrast with the regorafenib-alone or control group. This evidence concerns the gene MTOR and hepatocellular carcinoma.